Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Combioxin SA is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. RICCI, CRAIG D is the busiest examiner for the portfolio, responsible for 1 pending office action.
The company's filings are being evaluated by the examiners. With 2 pending office actions, the company must manage prosecution across the 2 identified art units within the Biotechnology & Pharmaceuticals sector. This distribution indicates that the 2 pending office actions are undergoing separate technical reviews.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431725 | TREATMENT OF SEPSIS AND SEPTIC SHOCK | AZPURU, CARLOS A | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759232 | Treatment of Pneumonia | RICCI, CRAIG D | 10d overdue |
| 18431725 | TREATMENT OF SEPSIS AND SEPTIC SHOCK | AZPURU, CARLOS A | 6d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759232 | Treatment of Pneumonia | RICCI, CRAIG D | 1611 | DP | Final Rejection | 10d overdue | Pending | Jun 28, 2024 |
| 18431725 | TREATMENT OF SEPSIS AND SEPTIC SHOCK | AZPURU, CARLOS A | 1617 | §112 | Final Rejection | 6d | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial